𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Growth factors in bladder cancer

✍ Scribed by M. Liebert


Publisher
Springer-Verlag
Year
1995
Tongue
English
Weight
927 KB
Volume
13
Category
Article
ISSN
0724-4983

No coin nor oath required. For personal study only.

✦ Synopsis


This article is an overview of peptide growth factors, their receptors, and signal-transduction pathways that play a role in bladder cancer. Included in this overview are epidermal growth factor receptor and its ligands, erbB2, fibroblast growth factors, insulin-like growth factor, the transferrin receptor, and transforming growth factor-beta. The use of growth factors or growth factor receptors for diagnostic and therapeutic interventions is also discussed.


📜 SIMILAR VOLUMES


Expression of epidermal growth factor re
✍ Peter Bue; Kenneth Wester; Anna Sjöström; Anders Holmberg; Sten Nilsson; Jörgen 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 French ⚖ 518 KB

Bladder cancers frequently exhibit an increased number of epidermal growth factor receptors (EGFR) in comparison to normal urothelium. The EGFR could potentially be a target for toxic conjugates. The aim of our study was to compare the expression of EGFR in metastases with concurrent or primary tumo

Detection of circulating cancer cells ex
✍ Iman Osman; Melissa Kang; Andy Lee; Fang-Ming Deng; David Polsky; Maryann Mikhai 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB 👁 1 views

## Abstract Our purpose was to determine the clinical relevance of the detection of circulating tumor cells (CTCs) expressing urothelial and epithelial markers in bladder cancer patients. Sixty‐two patients who presented to Memorial Sloan‐Kettering Cancer Center between July 2000 and September 2001

Heparin-binding epidermal growth factor-
✍ Christopher Kramer; Kai Klasmeyer; Hans Bojar; Wolfgang A. Schulz; Rolf Ackerman 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 313 KB 👁 1 views

## Abstract ## BACKGROUND. Cleavage of membrane‐anchored heparin‐binding epidermal growth factor‐like growth factor (proHB‐EGF) yields a soluble HB‐EGF isoform (sHB‐EGF), which is an activating epidermal growth factor receptor (EGFR) ligand and a C‐terminal fragment HB‐EGF‐C acting directly in the